ADCYAP1 and memory impairment: This idea is strengthened by other results that systemic application of synthetic human PACAP-38 reversed age-related memory impairment and also had a neuroprotective function in dopamine-based neurodegeneration developed in the Lymnaea parkinsonian model (Maasz et al. 2017; Pirger et al. 2014).